{
  "id": 20557697,
  "title": "Alphatec Holdings CFO John Koning buys $99,146 in common stock",
  "url": "https://urgent.news/2026/11/18/alphatec-holdings-cfo-john-koning-buys-99-146-in-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T06:46:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/alphatec-holdings-cfo-john-koning-buys-99146-in-common-stock-93CH-5034878"
  },
  "original_language": "en",
  "account": "On November 16, 2026, Alphatec Holdings' CFO John Koning made a notable investment in the company's own common stock, acquiring 14,601.7699 shares at a price of $6.79 per share. This transaction amounted to a total of approximately $99,146, bringing Koning's total holdings to 615,322.7699 shares of Alphatec Holdings common stock. Analysts believe the stock is currently undervalued, trading near its 52-week low of $6.71, with a significant 67% decline year-to-date, yet shows potential for upside appreciation. Notably, Alphatec Holdings' performance in the third quarter of 2026 fell short of Wall Street's expectations, with adjusted earnings of $0.09 per share, below the anticipated $0.10, and revenue of $221.17 million, missing the forecasted $225.44 million. Despite a 13% year-over-year revenue increase, weaker biologics sales and a reduced full-year outlook posed challenges. Analyst firms TD Cowen and Needham lowered their price targets for the company to $10 and $12, respectively, while maintaining a Buy rating. However, TD Cowen cited intensified biologics headwinds and a market slowdown as factors for their adjustment, while Needham's decision was influenced by the revenue miss and revised financial guidance.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}